Methods for selectively modulating a Th2-type response within a population of activated CD4+ T cells
AssigneeDana-Farber Cancer Institute, Inc.
InventorsGordon Freeman, Vassiliki Boussiotis, Lee Nadler
Life of this patent
Estimating the term…
Abstract
Methods for selectively modulating a Th2-type response within a population of activated CD4+ T cells are provided. The methods of the invention involve contacting the CD4+ T cells with an agent which modulates a B7-2-induced signal in the CD4+ T cells, such that the Th2-type response is modulated. Methods for either stimulating or inhibiting Th2 type responses are provided by the invention.
Claims21
1-22. (canceled)
A method for treating a subject having a condition that can be ameliorated by modulating a Th2-type response in the subject, comprising administering to the subject an agent which modulates a B7-2-induced signal in the CD4+ T cells, such that a Th2-type response is modulated in the subject to thereby ameliorate the condition in the subject.
The method of claim 3 1, wherein the autoimmune disease is rheumatoid arthritis.
42-59. (canceled)
Dependencies are inferred from the claim text.